10:26 AM EDT, 03/11/2024 (MT Newswires) -- Immuneering ( IMRX ) said Monday it has dosed the first patient in the phase 2a portion of a phase 1/2a trial of its IMM-1-104 immunotherapy in patients with various forms of cancer.

The company expects to eventually dose around 150 patients with 320 milligrams of IMM-1-104 once daily. either alone or in combination with other cancer therapies across five research arms, with a particular focus on treating patients with pancreatic ductal adenocarcinoma as well as certain types of melanoma and non-small cell lung cancer.

Initial phase 2 results are expected later this year, Immuneering ( IMRX ) said, adding topline data from the phase 1 portion of the trial are due out later in March.

Price: 6.55, Change: -0.01, Percent Change: -0.15